Population-level impact of semaglutide 2.4&#x2009;mg in patients with obesity or overweight and cardiovascular disease: A modelling study based on the SELECT trial

Cardiovascular Risk and Diseases

Comparison of Semaglutide or Dulaglutide Versus Empagliflozin for Risk for Death and Cardiovascular Outcomes Among Patients With Type 2 Diabetes : Two Target Trial Emulation Studies

Ann Intern Med

Saeed A, Mulukutla SR, Thoma F, Lemon L, Koczo A, Reis S, Marroquin O, Kip K

doi: 10.7326/ANNALS-24-00775

COMMENTED

Heart Failure

Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA(1c) levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial

★ 1 Recommended and commented by Prof. emer. Dr Ulrich Keller, Faculty Member

★ 2 Recommended by Prof. Dr Isabella Sudano, Faculty Member

Lancet Diabetes Endocrinol

Davies MJ, van der Meer P, Verma S, Patel S, Chinnakondepalli KM, Borlaug BA, Butler J, Kitzman DW, Shah SJ, Harring S, Salsali A, Rasmussen S, von Lewinski D, Abhayaratna W, Petrie MC, Kosiborod MN, STEP-HFpEF Trials Committees and Investigators

doi: 10.1016/S2213-8587(24)00304-8

Heart Failure

Risk of Heart Failure in Patients With Immune-Mediated Inflammatory Diseases: A Population-Based Study

J Rheumatol

Koppikar S, Kuriya B, Udell JA, Yu B, Chu A, Lee DS, Widdifield J, Eder L

doi: 10.3899/jrheum.2024-0866

Atrial Fibrillation

Impact of steatotic liver diseases on diabetes mellitus risk in patients with atrial fibrillation: a nationwide population study

Cardiovasc Diabetol

Ryu H, Lee SR, Choi EK, Go YH, Lee KY, Choi J, Han S, Kim JH, Ahn HJ, Kwon S, Kim BS, Han KD, Oh S, Lip GYH

doi: 10.1186/s12933-025-02795-5

RECOMMENDED

Thrombosis and Stroke

Association of Statin Treatment and Dose With the Clinical Course of Small Abdominal Aortic Aneurysms in Men: A 5-Year Prospective Cohort Study From 2 Population-Based Screening Trials

★ 2 Recommended by Prof. Dr Isabella Sudano, Faculty Member

Circulation

Skovbo JS, Obel LM, Diederichsen ACP, Steffensen FH, Frost L, Lambrechtsen J, Busk M, Urbonaviciene G, Egstrup K, Dahl M, Karon M, Rasmussen LM, Hallas J, Lindholt JS

doi: 10.1161/CIRCULATIONAHA.125.074544

Heart, Artery and Coronary Diseases

Time trends in mortality from heart failure and atherosclerotic cardiovascular disease in people with and without diabetes: a multi-national population-based study

Lancet Diabetes Endocrinol

Gong JY, Morton JI, Chen L, Sacre JW, Carstensen B, Gregg EW, Pavkov ME, Arffman M, Booth GL, Ter Braake JG, Chu LM, Fleetwood K, Fosse-Edorh S, Garbuviene M, Guion M, Ha KH, Kaul P, Ke C, Keskimäki I, Kim DJ, Laurberg T, Salim A, Støvring H, Vos RC, Wild SH, Fourlanos S, Shaw JE, Magliano DJ

doi: 10.1016/S2213-8587(25)00265-7

Cardiovascular Risk and Diseases

Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial

Lancet

Deanfield J, Lincoff AM, Kahn SE, Emerson SS, Lingvay I, Scirica BM, Plutzky J, Kushner RF, Colhoun HM, Hovingh GK, Stensen S, Weeke PE, Jeppesen OK, Bravo R, Wu CC, Komuro I, Santini F, Hjelmesæth J, Urina-Triana M, Buscemi S, Ryan DH

doi: 10.1016/S0140-6736(25)01375-3

Heart Failure

Obesity and Risk of Kidney Outcomes in Heart Failure With Preserved Ejection Fraction: A Participant-Level Pooled Analysis of 4 Contemporary Trials

JACC Heart Fail

Lassen MCH, Ostrominski JW, Claggett BL, Neuen BL, Beldhuis IE, Butt J, Biering-Sørensen T, Desai AS, Lewis EF, Jhund PS, Mc Causland F, Anand IS, Pfeffer MA, Pitt B, Zannad F, Zile MR, McMurray JJV, Solomon SD, Vaduganathan M

doi: 10.1016/j.jchf.2025.03.042

COMMENTED

Cardiovascular Risk and Diseases

Risk differences and underlying factors of cardiovascular events and mortality in patients with type 2 diabetes versus type 1 diabetes: a longitudinal cohort study of Swedish nationwide register data

★ 1 Recommended and commented by Prof. emer. Dr Ulrich Keller, Faculty Member

Lancet Diabetes Endocrinol

Patsoukaki V, Lind L, Lampa E, Radhi S, Eeg-Olofsson K, Eliasson B, Eriksson JW

doi: 10.1016/S2213-8587(25)00165-2

Related content

Comparison of Semaglutide or Dulaglutide Versus Empagliflozin for Risk for Death and Cardiovascular Outcomes Among Patients With Type 2 Diabetes : Two Target Trial Emulation Studies

Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA(1c) levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial

Risk of Heart Failure in Patients With Immune-Mediated Inflammatory Diseases: A Population-Based Study

Impact of steatotic liver diseases on diabetes mellitus risk in patients with atrial fibrillation: a nationwide population study

Association of Statin Treatment and Dose With the Clinical Course of Small Abdominal Aortic Aneurysms in Men: A 5-Year Prospective Cohort Study From 2 Population-Based Screening Trials

Time trends in mortality from heart failure and atherosclerotic cardiovascular disease in people with and without diabetes: a multi-national population-based study

Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial

Obesity and Risk of Kidney Outcomes in Heart Failure With Preserved Ejection Fraction: A Participant-Level Pooled Analysis of 4 Contemporary Trials

Risk differences and underlying factors of cardiovascular events and mortality in patients with type 2 diabetes versus type 1 diabetes: a longitudinal cohort study of Swedish nationwide register data